{"url":"https://newsforagent.com/news/2026-11-18/keiferx-third-line-summit-spotlight","markdown_url":"https://newsforagent.com/news/2026-11-18/keiferx-third-line-summit-spotlight.md","title":"KeifeRx to Spotlight Brain Health at Third Line Summit","headline":"KeifeRx CEO Chris Hoyt to Discuss Neurodegenerative Treatments at Washington Summit","description":"KeifeRx will headline a Partner Spotlight at The Third Line Summit on November 19, discussing its autophagy-restoring medicines and Phase 2 dementia results.","section":"Business","published_at":"2026-11-18T17:01:55+00:00","modified_at":"2026-11-18T17:01:55+00:00","author":"News Desk","key_takeaways":["KeifeRx will headline a Partner Spotlight conversation at The Third Line Summit on November 19, 2026, in Washington, DC.","KeifeRx's Phase 2 results in Lewy body dementia showed significant cognitive improvement and 70% fewer falls.","KeifeRx completed a $6 million Series A financing in December 2021 and is advancing kinase inhibitors for Alzheimer's and Parkinson's."],"companies":[{"name":"KeifeRx","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00031w2/keiferx","website":"https://www.keiferx.com"}],"source":{"publisher":"Business Wire","title":"KeifeRx to Headline Partner Spotlight on Brain Health Innovation at The Third Line Summit, November 19 in Washington, DC","url":"https://www.businesswire.com/news/home/20261118970008/en/"},"other_sources":[],"tags":["Business","KeifeRx"],"body_markdown":"KeifeRx will headline a Partner Spotlight conversation at The Third Line Summit on November 19, 2026, in Washington, DC, discussing its disease-modifying medicines for neurodegenerative diseases. [Business Wire](https://www.businesswire.com/news/home/20261118970008/en/) reported the event, which is invitation-only and runs from 9:00 AM to 3:00 PM at The City Tavern.\n\n## KeifeRx's Spotlight at the Third Line Summit\n\n[KeifeRx](https://akta.pro/company-profiles/00031w2/keiferx) is a Georgetown University spinout developing medicines that aim to restore autophagy, the cellular process that clears damaged proteins, while reducing inflammation and repairing blood vessels. CEO and board member Chris Hoyt will speak with Sia Anagnostou, Summit Co-Chair and Head of Programming & Strategic Partnerships at The Third Line Project, from 11:05 to 11:25 AM.\n\nThe conversation, titled \"Advancing Neurodegenerative Disease Treatment: From Discovery to Patient Care,\" will explore how research originating at Georgetown is being advanced toward investigational treatments. KeifeRx's drugs are designed to restore autophagy so the brain can clear toxic proteins, including amyloid and tau, that drive neurodegeneration.\n\nThe company began with a medicine that has human clinical data, including Phase 2 results in Lewy body dementia showing significant cognitive improvement and 70% fewer falls. KeifeRx has since created a transdermal gel formulation applied to the skin, with no pills to swallow. Upcoming trials are expected in patients with existing disease, with a path toward earlier settings.\n\nGeorgetown University owns several issued patents and pending patent applications on the underlying technology related to the use of kinase inhibitors for neurodegenerative diseases, with KeifeRx co-founder Charbel Moussa named as one of three inventors. KeifeRx holds an exclusive license to intellectual property from Georgetown University.\n\n## KeifeRx's Funding and Pipeline Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), KeifeRx completed a $6 million Series A financing on December 8, 2021, with the appointment of new board members. The same records show the company initiated Phase 1 patient enrollment in 2026 for KFRX03, its lead first-in-class small-molecule kinase inhibitor for Alzheimer's disease and its first clinical-stage asset.\n\nIn January 2026, KeifeRx entered a research collaboration and option agreement with Amneal Pharmaceuticals to advance KFRX06, a preclinical LRRK2 inhibitor for Parkinson's disease, with Amneal leading pre-IND research and a structured path to next-stage development and commercialization. Financial terms were not disclosed.\n\n## What Comes Next for KeifeRx\n\nThe Third Line Summit & Luncheon convenes approximately 150 leaders across health, science, food and culture under the theme \"What We Take In. What We Carry Forward.\" The event is scheduled for November 19, 2026, at The City Tavern, 3206 M St NW, Washington, DC.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}